Application
Western Blotting Analysis: A representative lot detected endogenous TC22 in human colorectal carcinoma T84 cell lysate, as well as recombinant human TC22, but not five other human TPM3 isoforms (Lin, J.L., et al. (2002). Gastroenterology. 123(1):152-162; Das, K.K., et al. (2009). Mol Pharmacol. 76(1):183-191).
ELISA Analysis: A representative lot specifically detected recombinant human TC22, but not five other human TPM3 isoforms (Das, K.K., et al. (2009). Mol Pharmacol. 76(1):183-191.).
Flow Cytometry Analysis: A representative lot detected time-dependent TC22 downregulation in LS180 cells upon 2 mM 5-Aminosalicylate (5-ASA) treatment (Das, K.K., et al. (2009). Mol Pharmacol. 76(1):183-191.)
Immunohistochemistry: Representative lots detected TC22 expression in human colon carcinoma and adenomatous polyp tissues, but not in normal colon tissue samples (Lin, J.L., et al. (2002). Gastroenterology. 123(1):152-162; Watari, J., et al. (2008). Clin Gastroenterol Hepatol. 6(4):409-17).
This Anti-TPM3 Antibody, isoform TC22, clone TC22-4 is validated for use in Western blotting, Immunohistochemistry, ELISA and FLow Cytometry for the detection of TPM3.
General description
Tropomyosins are dimmers of coiled-coil proteins that provide stability to actin filaments and regulate access of other actin-binding proteins. The human TPM3 gene (Gene ID 7170; also known as TM3, TM5, TRK, CFTD, NEM1, TM-5, TM30, CAPM1, TM30nm, TPMsk3, hscp30, HEL-189, HEL-S-82p, OK/SW-cl.5) encodes seven tropomyosin alpha-3 chain isoforms (UniProt P06753; also known as Tropomyosin-3) as a result of alternative splicing. Spliced variants 1, 2, 4, and 5 are also known as the skeletal muscle, TM30nm, TC22, and hTM5 isoform, respectively. The TC22 and the hTM5 variants are identical in sequence other than the 25 amino acids at their C-terminal end. TC22 is expressed in 100% of colorectal carcinomas, but is not expressed in normal colon epithelial cells. The anticarcinogenic potency of sulfasalazine (SASP) and its active metabolite 5-aminosalicylate (5-ASA, mesalamine) in protecting ulcerative colitis (UC) patients from developing colorectal cancer is directly linked to their efficacy in reducing cellular expression of TC22. Likewise, siRNA-mediated TC22 downregulation is shown to significantly alter several critical carcinogenic pathways in the human colon adenocarcinoma LS180 cells.
Immunogen
Recombinant human TC22 and boosts with TC22-specific C-terminal peptide.
Other Notes
Concentration: Please refer to lot specific datasheet.
Physical form
Format: Purified
Quality
Evaluated by Western Blotting in recombinant human TC22 protein.
Western Blotting Analysis: 0.5 µg/mL of this antibody detected TPM3 in 10 µg of recombinant human TC22 protein.
Specificity
Clone TC22-4 selectively detects human tropomyosin alpha-3 chain (TMP3) spliced variant TC22 (isoform 4), but not spliced Isoform 1 (Skeletal muscle), 2 (TM30nm), 3, 5 (hTM5), 6, or 7.
Target description
~32 kDa observed. Uncharacterized band(s) may appear in some lysates.
This product has met the following criteria to qualify for the following awards: